Edition:
United States

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

39.20USD
20 Jul 2018
Change (% chg)

$-0.10 (-0.25%)
Prev Close
$39.30
Open
$39.35
Day's High
$39.83
Day's Low
$38.65
Volume
71,432
Avg. Vol
218,599
52-wk High
$54.45
52-wk Low
$12.75

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $1,727.21
Shares Outstanding(Mil.): 43.95
Dividend: --
Yield (%): --

Financials

  ATRA.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -4.16 -- --
ROI: -39.44 -3.65 13.18
ROE: -40.24 -5.62 15.09

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

May 08 2018

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

May 08 2018

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Feb 28 2018

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

Feb 27 2018

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

Feb 27 2018

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

Feb 27 2018

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

Feb 21 2018

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $358.71 +0.60
Bayer AG (BAYGn.DE) €92.05 -0.30
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 8,401.00 -89.00
Merck KGaA (MRCG.DE) €85.84 -0.04
Sanofi SA (SASY.PA) €72.36 +0.25
Novartis AG (NOVN.S) CHF82.20 +1.24
Roche Holding Ltd. (ROG.S) CHF234.00 +2.05
Roche Holding Ltd. (RO.S) CHF238.60 +2.80

Earnings vs. Estimates